Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
625 Leser
Artikel bewerten:
(2)

Acron Group's Commercial Output Up 4.5% in Q1 2021

Finanznachrichten News

22 April 2021

Acron Group's Commercial Output Up 4.5% in Q1 2021

Group's consolidated output (including operating results for Acron, Dorogobuzh and

North-Western Phosphorous Company)

Product, '000 tQ1 2021Q1 2020YOY, %
MINERAL FERTILISERS
Ammonia6886771.6
incl. in-house consumption677634
Nitrogen fertilisers, including1,1701,1145.0
incl. in-house consumption170170
AN575604-4.8
incl. in-house consumption4653
Urea31924530.3
incl. in-house consumption124117
incl. prilled urea56131-57.1
incl. in-house consumption53
incl. granulated urea1510increase
incl. in-house consumption70
UAN2762654.1
Complex fertilisers, including611618-1.1
incl. in-house consumption89
NPK584590-1.0
incl. in-house consumption89
Bulk blends2728-4.8
Total commercial output for Mineral Fertilisers1,6151,5961.2
INDUSTRIAL PRODUCTS
Organic compounds, including1181125.2
incl. in-house consumption6255
Methanol2627-5.3
incl. in-house consumption2320
Formalin42406.0
incl. in-house consumption3835
Urea-formaldehyde resins504510.8
incl. in-house consumption11
Non-organic compounds, including29024916.5
Low-density and technical-grade AN1257861.0
Industrial urea4145-8.9
Calcium carbonate111113-2.1
Liquid carbon dioxide1212-0.8
Argon22-6.3
Total commercial output for Industrial Products34630613.2
PHOSPHATE INPUTS
Apatite concentrate31325622.5
incl. in-house consumption238209
Total commercial output for Apatite Concentrate754760.6
TOTAL COMMERCIAL OUTPUT2,0351,9484.5

Note: Commercial output is output less in-house consumption.

Comments from Chairman of Acron's Board of Directors Alexander Popov:

'In the first quarter of 2021, Acron Group produced 2,035,000 tonnes of its main commercial products. This is the third straight quarter that our commercial output has exceeded 2 million tonnes.

'The capacity-building projects completed in the past year have already delivered positive outcomes: ammonia output increased 2%, and urea output was up 30%. It is particularly satisfying that granulated urea output at the new unit put on stream in May 2020 is still growing, reaching 151,000 tonnes in the reporting period.

'We continue to focus on progressive development, with plans to further increase our commercial output. Construction of the Urea-6+ unit is underway, with expected commissioning in the second quarter of 2021. This new unit will add 520,000 tonnes of urea per annum to our total urea capacity.

'Today, almost all of the ammonia produced by Acron Group is processed in-house into finished products with high added value, so we are implementing projects to boost capacity at the Ammonia-2 and Ammonia-3 units in Veliky Novgorod. Once these two units are upgraded using the best available technology in 2023, they will provide all of the ammonia required by our Novgorod-based facility'.

Market Trends

Global urea prices grew rapidly in Q1 2021. Baltic FOB prices reached a seven-year record-high of USD 350. This sharp rise was driven by several factors, including strong seasonal demand in Europe and the United States, limited urea volume available for export from China, an increase in global prices for natural gas, and record-high grain prices. India's urea purchases give additional support to the market. However, the end of the high season in Europe and the United States and the expansion of Chinese exports may cause an excess of supply on the market, which could grow further this year with the commissioning of new production facilities in Africa and India.

In Q1 2021, AN and UAN prices also increased to their highest level in several years due to strong seasonal demand in the Northern Hemisphere and growth in urea prices used as a benchmark for other nitrogen fertiliser prices.

NPK prices increased in Q1 2021 as well, mainly driven by higher prices for basic products (urea, DAP, and potassium chloride). The increase in basic product prices outstripped blends because of their higher liquidity, so the NPK 16-16-16 premium over the basic product basket decreased to 5% from the historical average of 20%.

Average Indicative Prices, USD per t, FOB Baltic/Black Sea

Q1 2021Q4 2020Q1 2020Q1 2021/

Q4 2020

change
Q1 2021/

Q1 2020

change
NPK 16-16-1631226225219%24%
AN23416618741%25%
UAN21311912379%73%
Urea32623421739%50%
Ammonia32921122256%48%

Media Contacts:

Sergey Dorofeev

Anastasia Gromova

Tatiana Smirnova

Public Relations

Phone: +7 (495) 777-08-65 (ext. 5196)

Investor Contacts:

Ilya Popov

Investor Relations

Phone: +7 (495) 745-77-45 (ext. 5252)

Background Information

Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It owns transportation and logistics infrastructure, including three Baltic seaport terminals and distribution networks in Russia and China. Acron subsidiary North Atlantic Potash Inc. (NAP) holds mining leases and an exploration permit for ten parcels of the potassium salt deposit at Prairie Evaporite, Saskatchewan, Canada. Acron also holds a minority stake (19.8%) in Polish Grupa Azoty S.A., one of the largest chemical producers in Europe.

In 2020, the Group sold 7.8 million tonnes of main products to 74 countries, with Russia, Brazil, Europe and the United States as key markets.

In 2020, the Group posted consolidated IFRS revenue of RUB 119,864 million (USD 1,661 million), with EBITDA of RUB 35,311 million (USD 489 million). Acron's shares are traded on the Moscow Exchange and its global depositary receipts are traded at the London Stock Exchange (ticker AKRN). Acron employs over 11,000 people.

For more information about Acron Group, please visit www.acron.ru/en.


© 2021 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.